Takeda Launches Global Innovation Capability Center in Bengaluru
The ICC will focus on integrating cutting-edge technologies, including AI and generative AI (GenAI), to drive predictive analytics and efficiency in healthcare delivery.
Takeda, a leading global biopharmaceutical company, has inaugurated its Global Innovation Capability Center (ICC) in Bengaluru, marking its first such facility in Asia.
The center is part of Takeda’s Data, Digital & Technology (DD&T) organization, which focuses on developing advanced platforms, systems, applications, and artificial intelligence (AI) capabilities.
This initiative aims to enhance the evaluation and analysis of medical, clinical, commercial, scientific, and technical data.
Following successful ICC launches in Slovakia and Mexico, the Bengaluru facility highlights Takeda’s strategic commitment to leveraging data and digital technologies to transform patient care.
Takeda's Focus on Digital Innovation
Speaking at the launch, Tilak Banerjee, Head of Takeda ICC India, emphasized the role of the new center in advancing healthcare solutions.
“India was a natural choice for Takeda’s first ICC in Asia. This strategic commitment will create new jobs and further our mission of delivering life-transforming treatments to patients,” he said.
The ICC will focus on integrating cutting-edge technologies, including AI and generative AI (GenAI), to drive predictive analytics and efficiency in healthcare delivery.
It will also explore advancements in device engineering and application virtualization, supporting product innovation and personalized patient solutions.
Takeda’s efforts in India align with its broader mission to ensure sustainable healthcare access through strategic partnerships.
The company’s diverse therapeutic portfolio addresses areas such as gastrointestinal disorders, rare diseases, immunology, oncology, and vaccines.
Banerjee noted that the Bengaluru center would leverage Karnataka’s vibrant innovation ecosystem to address patient needs effectively.
Investing in Local Talent
Gabriele Ricci, Chief Data and Technology Officer at Takeda highlighted the importance of local expertise in driving innovation.
“Investing in India’s remarkable talent and technological expertise reflects our commitment to delivering data-driven solutions and sustainable growth,” he said.
The Bengaluru ICC aims to enhance data science and visualization capabilities to accelerate decision-making for better patient outcomes.
It will also support plasma-based therapies and improve donor experiences, contributing to the company’s vision for personalized healthcare solutions.
Sanjay Patel, Global Head of DD&T Innovation Capability Solutions & Services at Takeda, underscored the ICC’s role in future-proofing the company’s operations.
The Bengaluru facility complements Takeda’s ICCs in Slovakia, which employs 420 people, and Mexico, which recently expanded to a workforce of 180.
The new center is set to position Takeda as a leader in AI-driven healthcare innovation while enhancing its global footprint and impact.
Stay tuned for more such updates on Digital Health News.
Stay tuned for more such updates on Digital Health News
